On the stock market since 2014, it operates in the world of health and science. It has 1,073 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 13% a year on average.
Sales run at $320.6M a year. A small number, but proof the product has real buyers.
The average analyst price target is $5.92 — 73% above today’s price.
A loss of $136.0M against $320.6M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, ACB sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ACB is a high-risk stock — not yet profitable, and its future rides on its product catching on.